Anteris reports positive 30-day DurAVR THV outcomes in 100 small-annuli patients

Anteris Technologies Global Corp.

No valve-related mortality and no moderate/severe paravalvular leak at 30 days.
Mean gradient 8.2 mmHg; effective orifice area 2.2 cm², reflecting single-digit gradients.
97% freedom from moderate/severe prosthesis-patient mismatch vs 11-35% in SMART Trial.
Technical success rate 100% in the last 50 consecutive patient implants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.